Citius Oncology, Inc. (CTOR) vs Sera Prognostics, Inc. (SERA)
A side-by-side comparison of Citius Oncology, Inc. and Sera Prognostics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTOR
Citius Oncology, Inc.
$0.85HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SERA
Sera Prognostics, Inc.
$2.05HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CTOR vs SERA
growth of $100 · dividends reinvested · last 2yCTOR -92.4% (-72.4%/yr)SERA -73.8% (-48.8%/yr)SERA compounded faster over this window
CTOR SERA
CTOR vs SERA: by the numbers
- •CTOR is the larger company ($79M vs $78M market cap).
- •Both run net losses; CTOR's is the smaller (-648.32% vs -47475.71% net margin).
Metrics side by side
Valuation
| Metric | CTOR | SERA |
|---|---|---|
| Forward P/E | 8.50 | N/A |
| P/S ratio | 11.12 | 1118.45 |
| P/B ratio | 1.96 | 1.32 |
Profitability
| Metric | CTOR | SERA |
|---|---|---|
| Gross margin | 0.00% | -102.47% |
| Operating margin | 0.00% | -45066.67% |
| Net margin | -648.32% | -47475.71% |
| ROE | -114.06% | -55.97% |
| ROIC | -88.72% | -59.79% |
Growth (annualized)
| Metric | CTOR | SERA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 9.73% |
| Total return CAGR (5Y) | N/A | -28.91% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.